pillbase.ru

CINQAIR

Active substance: reslizumab

INJECTION, SOLUTION, CONCENTRATE · RESLIZUMAB 10 mg/mL

United StatesActive

Marketing holder: Teva Respiratory, LLC

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • Синкейро
    концентрат для приготовления раствора для инфузий, 10 мг/мл, 10 мл (original in Russian, GRLS)
    ЛП-004265
    Тева Фармацевтические Предприятия Лтд
EU 1
  • Cinqaero
    reslizumab
    EMEA/H/C/003912
    Teva B.V.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c5-1e3b-73bb-b46b-c29d10ab6c22;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208f-ff0f-772e-b3de-2768d33fb9e6;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
59310-610
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 59310-610 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 59310-610 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 59310-610 · Verified 2026-10-09 · open in source